Cargando…

Benefit/Risk Profile of Single-Inhaler Triple Therapy in COPD

Chronic obstructive pulmonary disease (COPD) is associated with major healthcare and socioeconomic burdens. International consortia recommend a personalized approach to treatment and management that aims to reduce both symptom burden and the risk of exacerbations. Recent clinical trials have investi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bourbeau, Jean, Bafadhel, Mona, Barnes, Neil C, Compton, Chris, Di Boscio, Valentina, Lipson, David A, Jones, Paul W, Martin, Neil, Weiss, Gudrun, Halpin, David M G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7935340/ https://www.ncbi.nlm.nih.gov/pubmed/33688176 http://dx.doi.org/10.2147/COPD.S291967

Ejemplares similares

Characteristics of New Users of Single- and Multiple-Inhaler Triple Therapy for COPD in Primary Care in England
por: Rothnie, Kieran J, et al.
Publicado: (2022)

INTREPID: single- versus multiple-inhaler triple therapy for COPD in usual clinical practice
por: Halpin, David M.G., et al.
Publicado: (2021)

Preventing clinically important deterioration with single-inhaler triple therapy in COPD
por: Naya, Ian, et al.
Publicado: (2018)

Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses
por: Halpin, David M.G., et al.
Publicado: (2018)

Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD
por: Bansal, Sandeep, et al.
Publicado: (2021)

Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study
por: Tabberer, Maggie, et al.
Publicado: (2020)

Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials
por: Ferguson, Gary T., et al.
Publicado: (2020)

Cost-Effectiveness of Single- versus Multiple-Inhaler Triple Therapy in a UK COPD Population: The INTREPID Trial
por: Halpin, David M G, et al.
Publicado: (2022)

Impact of baseline COPD symptom severity on the benefit from dual versus mono-bronchodilators: an analysis of the EMAX randomised controlled trial
por: Vogelmeier, Claus F., et al.
Publicado: (2020)

Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β(2)-Agonist Therapy: An Integrated Post Hoc Analysis
por: Naya, Ian P., et al.
Publicado: (2018)

Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT Trial
por: Gabrio, Andrea, et al.
Publicado: (2022)

Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial
por: Day, Nicola C., et al.
Publicado: (2020)

Blood eosinophils to guide inhaled maintenance therapy in a primary care COPD population
por: Ashdown, Helen F., et al.
Publicado: (2021)

Risk of Exacerbation and Pneumonia with Single-Inhaler Triple versus Dual Therapy in IMPACT
por: Dransfield, Mark T., et al.
Publicado: (2021)

Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial
por: Ismaila, Afisi S, et al.
Publicado: (2019)

Current appraisal of single inhaler triple therapy in COPD
por: Lipworth, Brian, et al.
Publicado: (2018)

Inhaled corticosteroids, blood eosinophils, and FEV(1) decline in patients with COPD in a large UK primary health care setting
por: Whittaker, Hannah R, et al.
Publicado: (2019)

Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study
por: Ismaila, Afisi S., et al.
Publicado: (2023)

Reply to: “Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies” [Letter]
por: Barnes, Neil C, et al.
Publicado: (2021)

Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial
por: Maltais, François, et al.
Publicado: (2019)

Comparative Adherence and Persistence of Single- and Multiple-Inhaler Triple Therapies Among Patients with Chronic Obstructive Pulmonary Disease in an English Real-World Primary Care Setting
por: Halpin, David M G, et al.
Publicado: (2022)

Inhaled budesonide for early treatment of COVID-19 – Authors' reply
por: Ramakrishnan, Sanjay, et al.
Publicado: (2021)

Cost-Effectiveness of Single-Inhaler Triple Therapy (FF/UMEC/VI) versus Tiotropium Monotherapy in Patients with Symptomatic Moderate-to-Very Severe COPD in the UK
por: Kendall, Robyn, et al.
Publicado: (2023)

Economic impact of implementing prescription of single-inhaler triple therapies versus current multiple-inhaler triple therapies for COPD in the Apulia Region
por: Resta, Emanuela, et al.
Publicado: (2022)

Functional Benefit of Smoking Cessation and Triple Inhaler in Combustible Cigarette Smokers with Severe COPD: A Retrospective Study
por: Pezzuto, Aldo, et al.
Publicado: (2022)

PROMETHEUS: Long-Term Exacerbation and Mortality Benefits of Implementing Single-Inhaler Triple Therapy in the US COPD Population
por: Criner, Gerard, et al.
Publicado: (2023)

The IMPACT Study – Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population
por: Kato, Motokazu, et al.
Publicado: (2019)

Inhaled corticosteroids in virus pandemics: a treatment for COVID-19?
por: Nicolau, Dan V, et al.
Publicado: (2020)

Eosinophilic inflammation, coronavirus disease 2019, and asthma: Are inhaled corticosteroids the missing link?
por: Ramakrishnan, Sanjay, et al.
Publicado: (2021)

Inhaled corticosteroids for the treatment of COVID-19
por: Bafadhel, Mona, et al.
Publicado: (2022)

Clinical effectiveness of once-daily fluticasone furoate/umeclidinium/vilanterol in usual practice: the COPD INTREPID study design
por: Worsley, Sally, et al.
Publicado: (2019)

Outcome of Inhaler Withdrawal in Patients Receiving Triple Therapy for COPD
por: Kim, Sae Ahm, et al.
Publicado: (2016)

Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD
por: Pavord, Ian D, et al.
Publicado: (2016)

Cost-effectiveness of roflumilast as an add-on to triple inhaled therapy vs triple inhaled therapy in patients with severe and very severe COPD associated with chronic bronchitis in the UK
por: Kiff, Chris, et al.
Publicado: (2018)

Discordant diagnostic criteria for pneumonia in COPD trials: a review
por: Wise, Robert A., et al.
Publicado: (2021)

The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial
por: Han, MeiLan K., et al.
Publicado: (2020)

Blood eosinophils: a biomarker of COPD exacerbation reduction with inhaled corticosteroids
por: Siddiqui, Salman H, et al.
Publicado: (2018)

Future concepts in bronchodilation for COPD: dual- versus monotherapy
por: Singh, Dave, et al.
Publicado: (2021)

Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait
por: David, Benjamin, et al.
Publicado: (2021)

A randomized, open-label, single-visit, crossover study simulating triple-drug delivery with Ellipta compared with dual inhaler combinations in patients with COPD
por: van der Palen, Job, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_obqvhl2i25i27hbbomtd07n86i